To date, PD-1-blocking therapies have shown limited efficacy in treating MM, although potential combination therapies may still prove beneficial, such as with the blockade of TIGIT, TIM3, and/or LAG3 [49,50]. The gene discussed is LAG3; the disease is Miyoshi myopathy.